Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Dr Lemuel A Moye III, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier:
NCT00684021
First received: May 22, 2008
Last updated: April 2, 2013
Last verified: April 2013
  Purpose

Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary arteries. If the clot becomes large enough, blood flow to the heart can be blocked almost completely and the heart muscle in that area can suffer permanent injury or death. Although a percutaneous coronary intervention (PCI) can be used to open up the blocked artery and restore blood flow to the heart muscle, there may be a significant amount of heart tissue that has been irreversibly damaged. Recent studies have shown that adult stem cells from bone marrow may be able to improve heart function after a heart attack. This study will evaluate the safety and effectiveness of using adult stem cells for improving heart function in people who have had a recent heart attack and a PCI.


Condition Intervention Phase
Left Ventricular Dysfunction
Biological: Adult stem cells
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Transplantation in Myocardial Infarction Evaluation (TIME) Protocol: A Phase II, Randomized, Controlled, Double-Blind Trial Evaluating the Effect of Timing on the Administration of Bone Marrow Mononuclear Cells (BMMNCs) Versus Placebo in Patients With Acute Myocardial Infarction

Resource links provided by NLM:


Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Global Left Ventricular Function [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular ejection fraction (global) as assessed via cardiac MRI. Values reported represent the change in Global EF from baseline to six months.

  • Regional Left Ventricular Function (Infarct Zone Wall Motion) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    One of two calculated values of regional left ventricular function as assessed via cardiac MRI. The infarct zone is defined as the cMRI segments with the largest 2 signal intensity enhancement measures with gadolinium (using a 17-segment model).Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.

  • Regional Left Ventricular Function (Border Zone Wall Motion) [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Two of two calculated values of regional left ventricular function assessed via cardiac MRI. The border zone is defined as those regions adjacent to the infarct zone in which the cMRI signal intensity enhancement were in the 10%-75% range. Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.


Secondary Outcome Measures:
  • Clincal and Safety Outcomes [ Time Frame: Measured from baseline to six months. ] [ Designated as safety issue: Yes ]
    Number of participants who experienced either death, reinfarction, repeat revascularizations (target and nontarget vessels) hospitalizations for heart failure, ICD placements

  • Left Ventricular Mass [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular mass (LV mass. Values reported represent the change in LV mass from baseline to six months.

  • End Diastolic Volume Index [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular end diastolic volume index. Values reported represent the change in LV end diastolic index from baseline to six months.

  • End Systolic Volume Index [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Left ventricular end systolic volume index. Values reported represent the change in LV end systolic volume index from baseline to six months.

  • Infarct Volume [ Time Frame: Measured at Baseline and Month 6 ] [ Designated as safety issue: No ]
    Infarct volume(mL). Values reported represent the change in infarct volume from baseline to six months.


Enrollment: 120
Study Start Date: July 2008
Study Completion Date: November 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
Biological: Adult stem cells
One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
Other Names:
  • Adult autologous stem cells
  • Bone marrow mononucleated cells
Active Comparator: 2
Participants will receive active adult stem cell infusion 7 days after PCI.
Biological: Adult stem cells
One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
Other Names:
  • Adult autologous stem cells
  • Bone marrow mononucleated cells
Placebo Comparator: 3
Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
Biological: Placebo
One time infusion of 30 ml of HSA (5%)
Other Name: HSA
Placebo Comparator: 4
Participants will receive placebo infusion (5% HSA) 7 days after PCI.
Biological: Placebo
One time infusion of 30 ml of HSA (5%)
Other Name: HSA

Detailed Description:

More than 1 million Americans suffer a heart attack each year, resulting in about a 38% mortality rate. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack. The permanent damage to the heart can lead to more severe problems, such as heart failure and irregular heartbeat, making the discovery of treatments to improve heart function after a heart attack important. Adult stem cells, which are immature cells that can become many different types of cells, may offer a potential means of reversing or preventing permanent damage caused by a heart attack. These specialized cells may have the ability to promote blood vessel growth, prevent cell death, and transform themselves into a number of tissues, including muscle. Recent studies have shown promise in using adult stem cells from bone marrow to reverse damage to the heart muscle caused by a heart attack, but more research is needed to assess the safety and effectiveness of stem cell use and to discover the best time to administer treatment. This study will evaluate the safety and effectiveness of placing adult stem cells into injured heart muscle for improving heart function in people who have had a recent heart attack and a PCI. Additionally, this study will help determine the best time to insert stem cells after a heart attack.

Participation in this study will last 24 months. All participants will first undergo baseline assessments that will include a medical history, a physical exam, an electrocardiogram (ECG), blood draws, an echocardiogram, and a magnetic resonance imaging (MRI) test. Participants will then be assigned randomly to receive stem cells or placebo either 3 or 7 days after their heart attack. The morning of the stem cell or placebo infusion, participants will undergo a blood draw and a bone marrow aspiration procedure of the hip bone to collect the stem cells. Later the same day, either stem cells or placebo will be infused through a catheter and into the damaged area of the heart.

For the first 24 hours following the infusion, participants will be asked to wear a small ECG machine called a Holter monitor. Participants will also be asked to record their temperature twice a day for a month after the infusion. Participants will return for follow-up visits at Months 1, 3, 6, 12, and 24 and will repeat many of the baseline assessments.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Patients at least 21 years of age
  2. Patients with first acute MI with successful primary percutaneous coronary intervention (PCI) in an artery at least 2.5 mm in diameter within 24 hours of onset of symptoms.
  3. No contraindications to undergoing cell therapy procedure within three to seven days following AMI and PCI.
  4. Hemodynamic stability as defined as no requirement for IABP, inotropic or blood pressure supporting medications.
  5. Ejection fraction following reperfusion with PCI <=45% as assessed by echocardiography.
  6. Consent to protocol and agree to comply with all follow-up visits and studies.
  7. Women of child bearing potential willing to use an active form of birth control.

Exclusion criteria

Patients will be excluded from the study if they meet any of the following conditions:

  1. History of sustained ventricular arrhythmias not related to their AMI (evidenced by previous holter monitoring and/or medication history for sustained ventricular arrhythmias in patient's medical chart).
  2. Require CABG or PCI due to the presence of residual coronary stenosis >70% luminal obstruction in the non-infarct related vessel (Additional PCI of non-culprit vessels may be performed prior to enrollment).
  3. History of any malignancy within the past five years excluding non-melanoma skin cancer or cervical cancer in-situ.
  4. History of chronic anemia (hemoglobin (Hb) <9.0 mg/dl).
  5. History of thrombocytosis (platelets >500k).
  6. History of thrombocytopenia in the absence of recent evidence that platelet counts are normal
  7. Known history of elevated INR (PT) or PTT.
  8. Life expectancy less than one year.
  9. History of untreated alcohol or drug abuse.
  10. Currently enrolled in another investigational drug or device trial
  11. Previous CABG.
  12. Previous MI resulting in LV dysfunction (LVEF <55%)
  13. History of stroke or transient ischemic attack (TIA) within the past six months.
  14. History of severe valvular heart disease (aortic valve area <1.0 cm2 or >3+ mitral regurgitation).
  15. Pregnancy or breast feeding
  16. Subjects with a known history of HIV, or has active hepatitis B,active hepatitis C, or active TB
  17. Patients with active inflammatory or autoimmune disease on chronic immuno-suppressive therapy.
  18. Contraindications to cMRI.
  19. Previous radiation to the pelvis with white blood cell count (WBC) and platelet counts below hospital specific normal values.
  20. Women child bearing potential not willing to practice an active form of birth control.
  21. Chronic liver disease that might interfere with survival or treatment with cell therapy.
  22. Chronic renal insufficiency as defined by a creatinine ≥ 2.0 mg/dL or requires chronic dialysis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00684021

Locations
United States, Florida
University of Florida-Department of Medicine
Gainesville, Florida, United States, 32610
United States, Minnesota
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
Texas Heart Institute
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Investigators
Study Chair: Robert Simari, MD Cardiovascular Cell Therapy Research Network
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr Lemuel A Moye III, Professor - School of Public Health, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT00684021     History of Changes
Other Study ID Numbers: 579, U01HL087318, 1 U01-HL-087318-01 (Project 1)
Study First Received: May 22, 2008
Results First Received: January 18, 2013
Last Updated: April 2, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by The University of Texas Health Science Center, Houston:
Acute Myocardial Infarction
Global Left Ventricular Ejection Fraction
Regional Left Ventricular Ejection Fraction
Left Ventricular Mass
Infarct Size
End Systolic Volume
End Diastolic Volume

Additional relevant MeSH terms:
Myocardial Infarction
Ventricular Dysfunction
Ventricular Dysfunction, Left
Cardiovascular Diseases
Heart Diseases
Myocardial Ischemia
Vascular Diseases

ClinicalTrials.gov processed this record on October 22, 2014